Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

Inovio's lead candidate, INO-3107 for recurrent respiratory papillomatosis (RRP), is under FDA accelerated-approval review, with a BLA action date of October 30, 2026. The company highlighted its clinical-stage DNA-medicines platform targeting HPV-related diseases, cancer and infectious diseases. A favorable FDA decision would be a material catalyst for Inovio, while the pending review remains a key regulatory risk.

Analysis

INO is a single-asset regulatory trade rather than a durable fundamentals re-rating at this stage. A favorable decision could produce an outsized near-term move because a rare-disease commercial asset would reduce the platform-discount applied to its DNA-medicine pipeline; however, the value realization will depend on launch execution, payer coverage, treatment-center adoption, and the size of the addressable recurrent procedure population. Those variables matter more over the subsequent 1-3 months than management’s conference messaging.

Accelerated-approval pathways create asymmetric downside if FDA requests additional evidence, narrows the indicated population, or imposes burdensome confirmatory-study requirements. Even approval may not eliminate financing risk: commercial buildout and post-marketing obligations can bring incremental cash burn before revenue is meaningful, leaving the stock sensitive to an equity raise in the 6-18 month window. The key falsifiers are any FDA communication suggesting CMC, safety, durability, or endpoint uncertainty; separately, post-decision guidance on launch spend and cash runway will determine whether an approval rally is sustainable.

EBS is not a clean sympathy beneficiary despite management overlap in infectious-disease experience; Inovio's outcome does not materially alter EBS earnings or valuation. The contrarian view is that the market may overvalue an approval headline while underweighting the limited liquidity, financing overhang, and difficulty converting a small rare-disease label into broad platform validation. Conversely, a clean approval accompanied by credible net-price, patient-start, and cash-runway disclosure could force short covering and justify holding exposure beyond the initial event.

Key Decisions for Investors

• Treat INO as a defined-risk event position only through the October 30 PDUFA date: use a small long via call spreads or stock sized to a full loss scenario rather than an unhedged core position. Do not add solely on conference-driven strength.
• For a post-approval long, wait for the first launch update and require evidence of adequate cash runway through the initial commercial ramp, disclosed payer access, and no material increase in operating-expense guidance. Absent those data, view a sharp approval-day rally as a trim opportunity rather than a 6-12 month hold.
• Set a downside trigger for any FDA delay, complete-response outcome, restrictive label, or confirmatory-trial commitment materially beyond current expectations; these developments would impair both time-to-revenue and financing capacity and warrant exiting long exposure.
• Avoid using EBS as a paired expression of the INO catalyst. There is no direct revenue, manufacturing, or regulatory read-through sufficient to offset INO-specific binary risk.